KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Arbutus Biopharma (ABUS) Preferred Dividend Payments (2017 - 2021)

Arbutus Biopharma (ABUS) has disclosed Preferred Dividend Payments for 5 consecutive years, with $574000.0 as the latest value for Q4 2021.

  • Quarterly Preferred Dividend Payments fell 81.62% to $574000.0 in Q4 2021 from the year-ago period, while the trailing twelve-month figure was $574000.0 through Sep 2022, down 96.09% year-over-year, with the annual reading at $12.1 million for FY2021, 0.13% changed from the prior year.
  • Preferred Dividend Payments hit $574000.0 in Q4 2021 for Arbutus Biopharma, down from $5.1 million in the prior quarter.
  • In the past five years, Preferred Dividend Payments ranged from a high of $5.1 million in Q3 2021 to a low of $574000.0 in Q4 2021.
  • Historically, Preferred Dividend Payments has averaged $2.7 million across 5 years, with a median of $2.8 million in 2019.
  • Biggest five-year swings in Preferred Dividend Payments: soared 190.56% in 2018 and later tumbled 81.62% in 2021.
  • Year by year, Preferred Dividend Payments stood at $911000.0 in 2017, then surged by 190.56% to $2.6 million in 2018, then increased by 8.8% to $2.9 million in 2019, then grew by 8.44% to $3.1 million in 2020, then tumbled by 81.62% to $574000.0 in 2021.
  • Business Quant data shows Preferred Dividend Payments for ABUS at $574000.0 in Q4 2021, $5.1 million in Q3 2021, and $3.3 million in Q2 2021.